stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Operating margin
CG Oncology, Inc.'s operating margin over the twelve months to 30 September 2026 was −4,293.5%, up 428.6 percentage points from fiscal 2025 (−4,722.1%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −4,722.1% | 5,345.12 |
| FY2024 | −10,067.3% | 17,113.63 |
| FY2023 | −27,180.9% | (8,727.48) |
| FY2022 | −18,453.4% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | −3,943.2% | 3,524.48 |
| Jun 2026 | −7,467.7% | (1,337.58) |
| Mar 2026 | −6,130.1% | (4,032.77) |
| Dec 2025 | −2,097.3% | 971.64 |
| 11 more quarters | Free account |
Operating margin against peers
| Company | Operating margin |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 12.8% |
| LGND Ligand Pharmaceuticals Incorporated compare | 9.29% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| SRRK Scholar Rock Holding Corporation compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −133.6% |
| CGON CG Oncology, Inc. | −4,056.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement